Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Accumulated Depreciation (2016 - 2019)

Historic Accumulated Depreciation for Viridian Therapeutics, Inc.\DE (VRDN) over the last 5 years, with Q1 2019 value amounting to $3.2 million.

  • Viridian Therapeutics, Inc.\DE's Accumulated Depreciation changed N/A to $3.2 million in Q1 2019 from the same period last year, while for Mar 2019 it was $3.2 million, marking a year-over-year change of. This contributed to the annual value of $3.1 million for FY2018, which is N/A changed from last year.
  • According to the latest figures from Q1 2019, Viridian Therapeutics, Inc.\DE's Accumulated Depreciation is $3.2 million.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Accumulated Depreciation registered a high of $3.2 million during Q1 2019, and its lowest value of $600000.0 during Q1 2015.
  • In the last 4 years, Viridian Therapeutics, Inc.\DE's Accumulated Depreciation had a median value of $786000.0 in 2016 and averaged $1.3 million.
  • As far as peak fluctuations go, Viridian Therapeutics, Inc.\DE's Accumulated Depreciation soared by 3372.86% in 2015, and later soared by 2731.21% in 2016.
  • Quarter analysis of 4 years shows Viridian Therapeutics, Inc.\DE's Accumulated Depreciation stood at $739000.0 in 2015, then increased by 19.22% to $881000.0 in 2016, then skyrocketed by 250.74% to $3.1 million in 2018, then increased by 2.23% to $3.2 million in 2019.
  • Its Accumulated Depreciation stands at $3.2 million for Q1 2019, versus $3.1 million for Q4 2018 and $881000.0 for Q3 2016.